Treatment Centre

Emerging treatments

Written and researched by Matt O’Brien, founder of Shift Some Timber.

Exciting does not mean approved. This section separates legitimate clinical development from hype, grey-market selling and social-media guesswork.

What we're tracking

Rule:

We will always show current status clearly: approved, under review, clinical trial or research only.

Flagship emerging treatment guide

Phase 3 results are remarkable. The UK status is equally important: it is not authorised for routine use. Our guide covers both.

Future medicines

Strong Phase 3 evidence, a different biological approach and big questions still to answer about UK approval and head-to-head performance.

Pipeline expanded

GLP-1 + amylin in one molecule, with oral and injectable development.

The once-daily oral GLP-1 authorised by the MHRA in the UK on 10 August 2026.

Monthly-or-less-frequent obesity treatment in Amgen's Phase 3 MARITIME research programme.

New comparison tool

Choose any two options and put them head-to-head — including Retatrutide, CagriSema, Amycretin, Orforglipron, MariTide, Mounjaro and Wegovy.

Check the underlying guidance directly: